

DESIGN OF EPIDEMIOLOGICAL TRIALS FOR VECTOR CONTROL PRODUCTS

REPORT OF A WHO EXPERT ADVISORY GROUP



CHÂTEAU DE PENTHES, GENEVA,
24–25 APRIL 2017



**World Health
Organization**

The support provided by the Bill and Melinda Gates Foundation (Grant No OPP1032376) for the work of Vector Control Advisory Group is gratefully acknowledged.

This report was produced by the Vector Ecology and Management Unit, Department of Control of Neglected Tropical Diseases, and the Entomology and Vector Control Unit of the Global Malaria Programme of the World Health Organization.

Design & Layout: Patrick Tissot WHO/HTM/NTD

DESIGN OF EPIDEMIOLOGICAL TRIALS FOR VECTOR CONTROL PRODUCTS

REPORT OF A WHO EXPERT ADVISORY GROUP



CHÂTEAU DE PENTHES, GENEVA,
24-25 APRIL 2017



**World Health
Organization**



© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-Non Commercial-Share Alike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Design of epidemiological trials for vector control products, Report of a WHO Expert Advisory Group, Chateau de Penthes, Geneva, 24–25 April 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Printed in France.

CONTENTS

1. EXECUTIVE SUMMARY -----	1
2. BACKGROUND -----	2
3. MEETING OBJECTIVES -----	3
4. REVIEW OF OUTDOOR RESIDUAL SPRAYING -----	4
4.1 Hierarchy of WHO-recommended trial designs -----	4
4.2 End-points for studies to demonstrate the public health value of new tool, strategies and approaches for vector control -----	6
4.3 Important considerations for trial design -----	7
4.4. Consensus statement on measurement of cost effectiveness -----	7
5. DESIGN OPTIONS FOR NEW VECTOR CONTROL PRODUCTS UNDER WHO EVALUATION -----	8
5.1 Consensus recommendations on efficacy trials for non-pyrethroid long-lasting insecticidal nets -----	8
5.2 Consensus recommendations on indoor residual spraying formulations with slow-acting insecticides and other tools that may require altered or new test approaches -----	9
5.3 Consensus recommendations on all other products in new product classes within the Vector Control Advisory Group portfolio -----	9
6. CONCLUSIONS AND FUTURE ACTIONS -----	10
ANNEXES -----	11
Annex 1. New vector control tools under evaluation by the Vector Control Advisory Group -----	11
Annex 2. Agenda -----	12
Annex 3. List of participants -----	13

GLOSSARY

Public health value: A product has public health value if it has proven protective efficacy to reduce or prevent infection and/or disease in humans.

Efficacy: An intervention measured when it is implemented under ideal, highly controlled circumstances; efficacy is typically measured in phase III studies.

Effectiveness: The degree of benefit of an intervention measured when it is delivered and used operationally under routine, "real-world" conditions; effectiveness is typically measured in phase IV studies.

1. EXECUTIVE SUMMARY

The World Health Organization (WHO) is mandated to provide guidance to Member States on matters of public health policy, including evidence-based policy recommendations for new vector control interventions. To that end, the Vector Control Advisory Group (VCAG) advises WHO on the value to public health of new vector control tools, including new products, technologies and approaches, intended to protect humans against pathogens transmitted by vectors. WHO recommends products for use in public health based on demonstrated evidence of their impact on diseases as well as safety and quality, but must reconcile the requirements for robust data to assess public health value with the urgent need for new tools to address critical threats (e.g. insecticide resistance and spread of Aedes-transmitted viruses). In response, WHO has called for an Expert Advisory Group (EAG) to review trial methodologies for evaluating data on the impact of new tools to prevent and control vector-borne diseases.

The recommendations developed by consensus of the Group emphasized the importance of randomized trials with robust study designs. Specific recommendations are provided on end-points, design considerations, and generation of evidence on the efficacy of long-lasting insecticidal nets (LLINs) that incorporate a non-pyrethroid class of insecticide (either alone or in combination with a pyrethroid insecticide) and on products that use indoor residual spraying (IRS) of insecticides with a novel entomological mode of action (e.g. slow-acting insecticides or insect growth regulators), which differ from the insecticides currently used for public health. The outcomes of this meeting will be used to inform the development of a WHO manual on trial designs for evaluating new vector control tools that are currently not covered by a WHO policy recommendation, for publication in 2017.

2. BACKGROUND

In accordance with WHO's mandate to provide guidance to Member States on matters of public health policy, the Organization develops evidence-based policy recommendations for new vector control tools, technologies and approaches. In 2012, an independent advisory body – the WHO Vector Control Advisory Group (VCAG) – was established to advise the Organization on the evaluation and validation of the public health value of new vector control tools, including new products, technologies and approaches, used to protect humans against pathogens transmitted by vectors.¹ VCAG reviews the potential of all new tools that target transmission of vectors-borne pathogens, such as those that transmit malaria and many neglected tropical diseases. The Group is jointly managed by the WHO's Global Malaria Programme and the Department of Control of Neglected Tropical Diseases.

Because WHO recommendations for new tools can have far reaching effects on disease control and prevention, these must be based on clear demonstration of protective efficacy through epidemiological outcomes. For example, WHO policy recommendations for malaria vector control² are based on robust evidence demonstrating that use of interventions such as LLINs³ and IRS⁴ reduces disease burden (morbidity and mortality). Consequently, countries have adopted these recommended interventions as part of their malaria control strategies, and this has contributed to massive declines in malaria incidence and mortality.⁵

For any new vector control tools in new product classes, WHO requires evidence from at least two well conducted, randomized controlled trials with epidemiological outcomes and follow up over at least two transmission seasons.⁶ With limited funds available for disease control, Member States are required to implement the most effective interventions for their local context. Epidemiological trials should therefore be conducted in different entomological and epidemiological settings⁷ in order to verify the public health value of the new product class or product variation. Two trials is the minimum number needed to assess generalizability.

Robust data are essential to assess the public health value of new product classes and to provide operational guidance. The type and extent of these data must be carefully balanced with the urgent need to make products available expeditiously to address threats

¹ The evaluation process for vector control products [Information note dated June 2017]. Geneva: World Health

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>